Loading...
•
Apr 01, 2022
STAAR Surgical Q1 2022 Earnings Report
STAAR Surgical's Q1 2022 earnings demonstrated record net sales and ICL unit growth, driven by increased surgeon and patient awareness.
Key Takeaways
STAAR Surgical reported record first-quarter net sales of $63.2 million, a 25% increase year-over-year. ICL sales grew by 26%, with unit growth up by 29%. The company reaffirmed its fiscal year 2022 net sales outlook of approximately $295 million, representing a 28% year-over-year growth.
Record net sales of $63.2 million, up 25% year-over-year.
ICL sales of $58.7 million, up 26% year-over-year.
Record ICL units increased 29% year-over-year.
Net income was $0.19 per share, compared to $0.10 per share in the prior year quarter.
Revenue by Segment
Forward Guidance
For fiscal year 2022, the company continues to anticipate approximately $295 million in net sales, which represents year-over-year growth of 28%.
Positive Outlook
- Reaffirming annual sales outlook of approximately $295 million.
- Strong global growth in China, Japan and India.
- FDA approval for EVO lenses.
- Commercialization of EVO in the U.S. is underway.
- Shipments of EVO lenses to China remain robust.
Challenges Ahead
- COVID-19 lockdowns in multiple cities in China.
- Global economic conditions
- Impact of the COVID-19 pandemic on markets
- International trade disputes
- Willingness of surgeons and patients to adopt new products
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...